NASDAQ:SMMTSUMMIT THERAPEU/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SUMMIT THERAPEU/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.67 +0.04 (+1.10 %) (As of 08/5/2020 04:00 PM ET) Add Compare Share Today's Range$3.65Now: $3.67▼$3.7550-Day Range$3.04MA: $3.41▼$3.8052-Week Range$1.18Now: $3.67▼$5.49Volume815 shsAverage Volume92,155 shsMarket Capitalization$117.81 millionP/E RatioN/ADividend YieldN/ABeta0.64 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingSUMMIT THERAPEU/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, SUMMIT THERAPEU/S has a potential upside of 9.0% from its current price of $3.67.Amount of Analyst CoverageSUMMIT THERAPEU/S has received no research coverage in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesSUMMIT THERAPEU/S has received 280 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSUMMIT THERAPEU/S has received 347 “underperform” votes. (Add your “underperform” vote.)Community SentimentSUMMIT THERAPEU/S has received 55.34% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about SUMMIT THERAPEU/S and other stocks. Vote “Outperform” if you believe SMMT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSUMMIT THERAPEU/S does not currently pay a dividend.Dividend GrowthSUMMIT THERAPEU/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SUMMIT THERAPEU/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 26.18% of the stock of SUMMIT THERAPEU/S is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for SUMMIT THERAPEU/S are expected to decrease in the coming year, from ($0.38) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SUMMIT THERAPEU/S is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SUMMIT THERAPEU/S is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSUMMIT THERAPEU/S has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.74 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SMMT Previous Symbol CUSIPN/A CIK1599298 Webwww.summitplc.com Phone44-12-3544-3939Debt Debt-to-Equity Ratio0.01 Current Ratio4.80 Quick Ratio4.80Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$56.50 million Price / Sales2.09 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book3.53Profitability EPS (Most Recent Fiscal Year)N/A Net Income$9.99 million Net Margins-3,844.44% Return on Equity-61.99% Return on Assets-44.72%Miscellaneous Employees61 Outstanding Shares32,100,000Market Cap$117.81 million Next Earnings DateN/A OptionableOptionable $3.67 +0.04 (+1.10 %) (As of 08/5/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SMMT News and Ratings via Email Sign-up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions How has SUMMIT THERAPEU/S's stock been impacted by COVID-19 (Coronavirus)? SUMMIT THERAPEU/S's stock was trading at $1.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SMMT stock has increased by 94.2% and is now trading at $3.67. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of SUMMIT THERAPEU/S? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SUMMIT THERAPEU/S. How were SUMMIT THERAPEU/S's earnings last quarter? SUMMIT THERAPEU/S (NASDAQ:SMMT) announced its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.13. The business had revenue of $0.66 million for the quarter, compared to analysts' expectations of $4.44 million. SUMMIT THERAPEU/S had a negative net margin of 3,844.44% and a negative return on equity of 61.99%. View SUMMIT THERAPEU/S's earnings history. What price target have analysts set for SMMT? 1 equities research analysts have issued twelve-month target prices for SUMMIT THERAPEU/S's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate SUMMIT THERAPEU/S's share price to reach $4.00 in the next year. This suggests a possible upside of 9.0% from the stock's current price. View analysts' price targets for SUMMIT THERAPEU/S. Has SUMMIT THERAPEU/S been receiving favorable news coverage? News coverage about SMMT stock has trended neutral recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. SUMMIT THERAPEU/S earned a news sentiment score of 0.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about SUMMIT THERAPEU/S. Who are some of SUMMIT THERAPEU/S's key competitors? Some companies that are related to SUMMIT THERAPEU/S include XBiotech (XBIT), DURECT (DRRX), Tocagen (TOCA), Protagonist Therapeutics (PTGX), BELLUS Health (BLUSF), Puma Biotechnology (PBYI), Catalyst Pharmaceuticals (CPRX), BioDelivery Sciences International (BDSI), Rigel Pharmaceuticals (RIGL), Avid Bioservices (CDMO), Zafgen (ZFGN), Liminal BioSciences (LMNL), Spectrum Pharmaceuticals (SPPI), 89bio (ETNB) and Xenon Pharmaceuticals (XENE). View all competitors. What other stocks do shareholders of SUMMIT THERAPEU/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other SUMMIT THERAPEU/S investors own include Energy Transfer LP Unit (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Catabasis Pharmaceuticals (CATB), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Dynavax Technologies (DVAX), Ford Motor (F) and Martin Midstream Partners (MMLP). Who are SUMMIT THERAPEU/S's key executives? SUMMIT THERAPEU/S's management team includes the following people: Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)Ms. Melissa Strange FCCA, VP of Fin. & Company Sec. (Age 39)Ms. Michelle Avery, Director of Investor Relations When did SUMMIT THERAPEU/S IPO? (SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager. What is SUMMIT THERAPEU/S's stock symbol? SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT." Who are SUMMIT THERAPEU/S's major shareholders? SUMMIT THERAPEU/S's stock is owned by a variety of institutional and retail investors. Top institutional investors include UBS Group AG (0.39%), Cornerstone Investment Partners LLC (0.11%) and M&T Bank Corp (0.08%). Which major investors are buying SUMMIT THERAPEU/S stock? SMMT stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, Cornerstone Investment Partners LLC, and M&T Bank Corp. How do I buy shares of SUMMIT THERAPEU/S? Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is SUMMIT THERAPEU/S's stock price today? One share of SMMT stock can currently be purchased for approximately $3.67. How big of a company is SUMMIT THERAPEU/S? SUMMIT THERAPEU/S has a market capitalization of $117.81 million and generates $56.50 million in revenue each year. SUMMIT THERAPEU/S employs 61 workers across the globe. What is SUMMIT THERAPEU/S's official website? The official website for SUMMIT THERAPEU/S is www.summitplc.com. How can I contact SUMMIT THERAPEU/S? SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected] This page was last updated on 8/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
